REGLYDE: A Clinical Trial to Enhance the Brain's Natural Defenses in Alzheimer's
Together, let's advance innovative, non-invasive brain therapy
ALZHEIMER'S
The Challenge: A Devastating Disease
Alzheimer’s disease shatters lives, robbing millions of their memories, their independence, and the essence of who they are.
It’s a crisis that extends beyond individuals, placing an immense emotional and physical burden on their families and loved ones.
Imagine if there was a way to restore hope, offering a chance to reclaim memories, bring back our loved ones, and embrace life once again.
We have made a significant discovery that could forever change how we think about Alzheimer’s. It’s time to stop fighting the brain and start working with it!
ALZHEIMER'S
Our Hypothesis
The brain consumes large amounts of energy and generates waste products that must be efficiently cleared to maintain function and health. This process depends on cerebrospinal fluid (CSF), a clear fluid that surrounds the brain and spinal cord while delivering nutrients and removing toxins. Spinal movements play a crucial role in driving CSF circulation, a natural mechanism our bodies support through regular physical activity.
Unfortunately, modern sedentary lifestyles disrupt this essential circulation, contributing to reduced nutrient delivery, toxic buildup, and an increased risk of neurodegenerative diseases like Alzheimer’s. Traditional movement philosophies like yoga and qigong intuitively recognized the importance of spinal movements for mental and cognitive well-being.
At Ciatrix, we’re integrating these ancient practices with the latest advancements in neuroscience to gain powerful insights into how movement can enhance brain health and combat Alzheimer’s.
Research shows that the brain's waste removal system (the glymphatic system) is most active during sleep and states of deep relaxation. By combining deep relaxation techniques with calibrated spinal movements, we can create a powerful synergy that optimizes these natural processes, enhancing cognitive clarity and overall brain health.
We believe that enhancing CSF circulation through targeted, evidence-based spinal movements could revolutionize brain health, mitigating or reversing neurodegenerative conditions such as Alzheimer’s. Our mission is to develop clinically validated movement protocols and make them accessible to all.
ALZHEIMER'S
The Power of Yoga
At Ciatrix, we’re doing what hasn’t been done before: merging gentle yoga-like movements, mindful breathing, and cutting-edge technology, while rigorously testing it in a clinical trial, to prove, once and for all, that relaxation-based movement therapy truly works.
Our unique approach could give patients and caregivers a new path toward hope and relief. Yoga is a proven method to enhance cognitive clarity, reduce stress, and support brain health, offering significant potential against neurodegenerative diseases. Traditional yoga poses and routines can be challenging for some, including individuals with limited mobility or older adults.
However, yoga’s profound neurological benefits should be accessible to everyone.
By standardizing yoga, testing it in a clinical setting, and making it easier for all to participate, we aim to ensure that people of all ages and abilities can benefit from its ability to support brain health and combat neurodegenerative diseases.
The Fluere™ Device
To test our hypothesis, we have designed and manufactured an innovative device to investigate its potential to promote cerebrospinal fluid flow and, in turn, enhance brain function and overall health.
The Fluere™ device is designed to guide gentle, rhythmic spinal movements. This approach is based on the hypothesis that such movements may create subtle pressure changes, which our clinical trial is investigating for their potential to encourage cerebrospinal fluid (CSF) circulation within the central nervous system.
The REGLYDE clinical trial further aims to explore whether these precise, device-guided motions, by potentially influencing CSF dynamics, could support cognitive function, aspects of neurological health, and overall well-being in individuals with early-stage Alzheimer's disease.
Computer-Guided
Yoga Movement
Gentle Device-Mediated Motions: The Fluere™ device guides the body through safe, subtle movements similar to those found in yoga and qigong.
Mindful Breathing
and Relaxation
Fluere™ uses calming music and guided inhale/exhale cues through headphones with the hopes of promoting deep relaxation, enhancing heart rate variability (HRV), and supporting cognitive and emotional well-being.
Real Time Monitoring and Data Collection
In our clinical trials, we use advanced optical sensors to measure brain fluid flow and assess how movement impacts brain health. Participants also wear activity monitors that track heart rate, HRV, and blood pressure, providing insights into sleep, recovery, and helping us refine and personalize the therapy.
Universal &
Safe Access
Fluere™ is designed for universal access, auto-calibrating each session to the user’s abilities and safely supporting individuals up to 135 kg, including those with some mobility or cognitive challenges.
Diving Deeper: Inside the REGLYDE Clinical Trial
About The Study
This clinical trial investigates the safety, tolerability, and feasibility of the Fluere™ therapy for individuals with early-stage Alzheimer’s disease (AD stages 3 and 4). Over four weeks, participants receive 12 sessions combining movement, rhythmic breathing, and music-guided relaxation.
What We're Studying
The primary goals are to assess how well participants tolerate the therapy and whether a longer regimen is feasible. Secondary goals include monitoring improvements in posture, heart rate variability, sleep quality, cognitive function, and key biomarkers of neurodegeneration.
Study Duration
The treatment period will last for 4 weeks, involving a total of 12 therapy sessions. There is typically a one-week interval between the initial screening visit (T0) and the first therapy session (T1).
ALZHEIMER'S
Why Your Support Matters
Running a transparent and honest clinical trial in today’s climate, which is often riddled with conflicts of interest, requires significant resources.
We need your help to fund:
Multi-Center
Expansion:
To achieve statistical significance and ensure replicability of results, we aim to test Fluere™ at two hospitals in the Czech Republic and one in Slovakia. With additional funding, we plan to expand the study to more centers around the world.
High-Quality Equipment & Participant Care:
Your donations help cover the costs of manufacturing Fluere™ devices, developing monitoring sensors and software, and providing participant compensation and travel reimbursements. This support ensures that everyone can fully commit to the clinical trial.
Research &
Development:
We’ll refine the therapy, establish safety protocols for different fitness levels and disease stages, and continue testing dosage. A rigorous trial with 24 participants and 24 controls will cost $500,000 to $750,000, covering equipment, staff, data analysis, and ethical compliance.
Who are we?
Ciatrix is a team of innovators, scientists, and medical experts united by a mission to revolutionize Alzheimer’s care. By combining cutting-edge neuroscience, innovative technology, and a commitment to improving lives, we’re leading the way in accessible, non-invasive solutions to neurodegenerative diseases.
Zdenko Grajcar
A trailblazer in neurotechnology with 250+ patents, Zdenko blends a passion for innovation with decades of R&D expertise. As Founder and CEO of Ciatrix, he brings a track record of startup success to his mission: creating non-invasive, accessible solutions for millions affected by neurodegenerative diseases.
Founder and CEO
Nash Rittmann, BBA
As Chief Operating Officer, Nash ensures seamless execution of Ciatrix’s initiatives, leveraging his expertise in strategic operations and business development.
Chief Operating Officer
Dr. Katerina Sherdova,PhD
As Head of the Memory Center at ICRC, Dr. Sherdova brings extensive experience in dementia research and preventive care, driving Ciatrix’s innovative therapeutic approaches.
Director of Clinical Research
Dr. Patrik Simko, PhD
A neuroscience advisor and director of clinical research, Dr. Simko specializes in neurodegenerative research and cognitive restoration. With a strong background in data science, neurotech consulting, and clinical research, he brings a holistic approach to advancing brain health.
Clinical Research Consultant